Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ziftomenib

An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:menin-KMT2A inhibitor KO 539
menin-mixed lineage leukemia protein-protein interaction inhibitor KO 539
menin-MLL inhibitor KO-539
menin-MLL interaction inhibitor KO 539
Code name:KO 539
KO-539
KO539
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search